Explainer
Cancer immunotherapy side effects explained
Immunotherapy side effects mostly happen because an immune system revved up against cancer also attacks healthy tissue, and they can appear at any point during or after treatment.[1] They are often mild and reversible, but some are severe, and guideline management is organised around toxicity grades and corticosteroids.[2][3]
Immunotherapy works by taking the brakes off the immune system or arming it with new targets. The side effects follow from the same mechanism: NCI says many of them happen because an immune system revved up against the cancer also acts against healthy cells and tissues, and that they can appear at any point during or after treatment.[1] A 2020 review describes them as differing from the side effects of older cancer treatments, typically with a delayed onset and a prolonged course.[4]
This page is general information, not medical advice. Report new symptoms during or after immunotherapy to your cancer team promptly, and talk to a clinician about your own treatment.
What the side effects look like
With checkpoint inhibitors, rash, diarrhoea and fatigue are common. Rarer effects include widespread inflammation that can affect the lungs, colon, liver, heart or thyroid.[5] NCI says severe or fatal allergic and inflammation-related reactions can happen with some types of immunotherapy, but that these are rare.[6]
Immune-related adverse events (irAEs) differ from classical cytotoxic toxicity: a 2020 Nature Reviews Disease Primers review describes them as typically delayed in onset and prolonged in duration, and able to involve any organ or system.[4] With checkpoint blockade, the rarer inflammatory effects can reach organs including the lungs, colon, liver, heart and thyroid.[5]
How often they happen
Frequency depends on the drug and the combination. In one ipilimumab melanoma trial, 64% of patients had an immune-related adverse event of any grade and 18% had one of grade 3 or higher.[7] Figures like these come from specific trial populations and do not transfer to other drugs or other patients.
Cell and antibody therapies have their own toxicities
CAR-T and T-cell engagers can cause cytokine release syndrome: very high fevers and sharp falls in blood pressure. Some patients get neurological symptoms such as confusion or trouble speaking, known as ICANS.[8] Labels for T-cell engagers such as tarlatamab and teclistamab carry boxed warnings for both.[9]
Cytokine release syndrome and ICANS are the defining acute toxicities of immune effector cell therapies.[8] Their grading varied widely between trials and institutions until a 2018 expert meeting produced the ASTCT consensus grading system, intended for use both in trials and in routine care.[10] For approved autologous CAR-T products, the FDA required a class boxed warning in April 2024 for T-cell malignancies, with life-long monitoring for secondary cancers, and in June 2025 removed their REMS programmes, cutting the recommended stay near a treatment centre from four weeks to two.[11][12]
How they are managed
ASCO’s 2021 guideline update sets out management by grade for checkpoint inhibitors: generally continue therapy with close monitoring at grade 1, consider suspending it for most grade 2 toxicities, suspend it and start high-dose corticosteroids at grade 3, and discontinue permanently at grade 4, except for hormone-related effects controlled by hormone replacement.[3] The 2020 review describes management as resting primarily on corticosteroids and other immunomodulatory drugs, which it says should be prescribed carefully to reduce short- and long-term complications.[2] Those are the guideline’s thresholds, not instructions: dose and timing decisions belong to the treating team.
How strong the evidence is
The ASCO panel reviewed 175 eligible studies and stated that, because of the paucity of high-quality evidence, its recommendations are based on expert consensus.[13] In other words, the guideline’s management steps rest mainly on expert agreement rather than on high-quality comparative trials.
What to take from it
Most immune-related effects are low grade, treatable and reversible; some are severe and can leave permanent disorders.[2] NCI notes that effects can appear at any point during or after treatment, so they are not confined to the weeks of treatment itself.[1]
More in this series: the cancer immunotherapy crash course and how CAR-T cell therapy works.
Read next
Immune checkpoint inhibitors
Checkpoint inhibitors such as pembrolizumab release immune brakes like PD-1 and CTLA-4. How they work, who responds, side effects and 2026 approvals.
Questions readers ask
Why does immunotherapy cause side effects at all?
NCI says many of them happen because an immune system revved up to act against the cancer also acts against healthy cells and tissues, and that they can occur at any point during and after treatment.[1]
What are the common checkpoint inhibitor side effects?
Rash, diarrhoea and fatigue are common. Rarer effects include widespread inflammation that can affect organs such as the lungs, colon, liver, heart and thyroid.[5]
How often are they serious?
It depends on the drug. In one ipilimumab melanoma trial, 64% of patients had an immune-related adverse event of any grade and 18% had one of grade 3 or higher. NCI says severe or fatal reactions are rare.[7][6]
What is cytokine release syndrome?
The main acute toxicity of CAR-T and T-cell engagers, which can cause dangerously high fevers and steep drops in blood pressure, alongside neurotoxicity (ICANS) with symptoms such as confusion and impaired speech.[8][9]
How are these effects managed?
ASCO's 2021 guideline describes continuing therapy with close monitoring at grade 1, possibly suspending it for most grade 2 effects, suspending it with high-dose corticosteroids at grade 3, and stopping permanently at grade 4, with exceptions for hormone-related effects controlled by replacement.[3]
How good is the evidence behind the guidance?
The ASCO panel reviewed 175 eligible studies and said that because of the paucity of high-quality evidence its recommendations rest on expert consensus.[13]
Sources
· 13 claims from 7 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
NCI says many immunotherapy side effects happen because an immune system revved up against the cancer also acts against healthy cells and tissues, and that side effects can appear at any point during or after treatment. confirmedas of 2023-02-16
- Immunotherapy Side Effects · National Cancer Institute · Primary source · 2023-02-16 (retrieved 2026-11-14)
- Immunotherapy Side Effects · National Cancer Institute · Primary source · 2023-02-16 (retrieved 2026-11-14)
- [2]
The same review says these effects are frequently low grade, treatable and reversible, but that some can be severe and lead to permanent disorders, and that management rests primarily on corticosteroids and other immunomodulatory drugs. confirmedas of 2020-05-07
- Immune-related adverse events of checkpoint inhibitors (Nature Reviews Disease Primers, 2020; Europe PMC record) · Nature Reviews Disease Primers (via Europe PMC) · Primary source · 2020-05-07 · Abstract (retrieved 2026-11-14)
- Immune-related adverse events of checkpoint inhibitors (Nature Reviews Disease Primers, 2020; Europe PMC record) · Nature Reviews Disease Primers (via Europe PMC) · Primary source · 2020-05-07 · Abstract (retrieved 2026-11-14)
- [3]
ASCO's 2021 guideline update describes management by toxicity grade: generally continue checkpoint inhibitor therapy with close monitoring at grade 1, consider suspending it for most grade 2 toxicities, suspend it and start high-dose corticosteroids at grade 3, and permanently discontinue at grade 4, except for hormone-related effects controlled by hormone replacement. confirmedas of 2021-11-01
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Recommendations (retrieved 2026-11-14)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Recommendations (retrieved 2026-11-14)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Recommendations (retrieved 2026-11-14)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Recommendations (retrieved 2026-11-14)
- [4]
A 2020 Nature Reviews Disease Primers review says immune-related adverse events differ from the side effects of older cancer treatments, typically having a delayed onset and prolonged duration, and that they can involve any organ or system. confirmedas of 2020-05-07
- Immune-related adverse events of checkpoint inhibitors (Nature Reviews Disease Primers, 2020; Europe PMC record) · Nature Reviews Disease Primers (via Europe PMC) · Primary source · 2020-05-07 · Abstract (retrieved 2026-11-14)
- Immune-related adverse events of checkpoint inhibitors (Nature Reviews Disease Primers, 2020; Europe PMC record) · Nature Reviews Disease Primers (via Europe PMC) · Primary source · 2020-05-07 · Abstract (retrieved 2026-11-14)
- [5]
Common side effects of checkpoint inhibitors include rash, diarrhoea and fatigue; rarer effects include widespread inflammation that can affect organs such as the lungs, colon, liver, heart and thyroid. confirmedas of 2026-10-10
- Immune Checkpoint Inhibitors · National Cancer Institute · Primary source (retrieved 2026-10-10)
- [6]
NCI says some types of immunotherapy may cause severe or fatal allergic and inflammation-related reactions, but that such reactions are rare. confirmedas of 2023-02-16
- Immunotherapy Side Effects · National Cancer Institute · Primary source · 2023-02-16 (retrieved 2026-11-14)
- [7]
In an ipilimumab melanoma trial, 64% of patients had an immune-related adverse event of any grade and 18% had one of grade 3 or higher. confirmedas of 2026-10-10
- Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer · Journal of the Advanced Practitioner in Oncology · Primary source · 2014-11-01 (retrieved 2026-10-10)
- [8]
The main acute CAR-T toxicities are cytokine release syndrome, which can cause dangerously high fevers and steep drops in blood pressure, and neurotoxicity (ICANS), with symptoms such as confusion and impaired speech. confirmedas of 2025-02-26
- CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers · National Cancer Institute · Primary source · 2025-02-26 (retrieved 2026-10-10)
- [9]
T-cell engager labels such as tarlatamab's and teclistamab's carry boxed warnings for cytokine release syndrome and neurologic toxicity including ICANS. confirmedas of 2026-03-05
- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer · US Food and Drug Administration · Primary source · 2024-05-16 (retrieved 2026-10-10)
- FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma · US Food and Drug Administration · Primary source · 2026-03-05 (retrieved 2026-10-10)
- [10]
Grading of cytokine release syndrome and immune-cell neurotoxicity varied between trials and hospitals until a 2018 expert meeting produced the ASTCT consensus grading system, intended for use in trials and routine care. confirmedas of 2018-12-25
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells (2019; Europe PMC record) · Biology of Blood and Marrow Transplantation (via Europe PMC) · Primary source · 2018-12-25 · Abstract (retrieved 2026-11-14)
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells (2019; Europe PMC record) · Biology of Blood and Marrow Transplantation (via Europe PMC) · Primary source · 2018-12-25 · Abstract (retrieved 2026-11-14)
- [11]
In April 2024 the FDA required a boxed warning on six approved BCMA- or CD19-directed autologous CAR-T products for the risk of T-cell malignancies, and said patients should be monitored life-long for secondary cancers. confirmedas of 2024-04-18
- FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous CAR T cell Immunotherapies · US Food and Drug Administration · Primary source · 2024-04-18 (retrieved 2026-10-10)
- [12]
In June 2025 the FDA removed the REMS safety programmes for approved autologous CAR-T therapies, cutting the recommended stay near a treatment centre from four weeks to two and the driving restriction from eight weeks to two. confirmedas of 2025-10-02
- Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access · Cancers (MDPI) · Primary source · 2025-10-02 (retrieved 2026-10-10)
- [13]
ASCO's guideline panel reviewed 175 eligible studies and said that because of the paucity of high-quality evidence its recommendations are based on expert consensus. confirmedas of 2021-11-01
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Results (retrieved 2026-11-14)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Journal of Clinical Oncology, 2021; Europe PMC record) · Journal of Clinical Oncology (via Europe PMC) · Primary source · 2021-11-01 · Results (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 14, 2026. Next scheduled review: Aug 11, 2027.
Cite this page
"Cancer immunotherapy side effects explained." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/cancer-immunotherapy-side-effects-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.